Skip to main
AMGN

Amgen (AMGN) Stock Forecast & Price Target

Amgen (AMGN) Analyst Ratings

Based on 22 analyst ratings
Hold
Strong Buy 14%
Buy 27%
Hold 55%
Sell 5%
Strong Sell 0%

Bulls say

Amgen is forecasted to report slightly weaker earnings and revenue for the second quarter of 2026 compared to consensus estimates, but overall is expected to perform within its own guidance for the full year of 2026. The company has a strong portfolio of flagship drugs in various therapeutic areas and has made recent acquisitions to bolster its rare disease and oncology offerings. Upside risks include strong pipeline data and better-than-expected performance from current products. Downside risks include disappointing pipeline data and regulatory or pricing concerns. Investors should watch for updates on the adoption of key growth drivers and potential catalysts on the company's earnings conference call. With continued growth expected from the rare disease segment and potential for greater adoption of key products like Uplizna and Imdelltra in small cell lung cancer, Amgen's stock is expected to have upside potential, although there are some risks to consider.

Bears say

Amgen is poised for near-term growth with upcoming catalysts such as the potential approval of Dazodalibep and Tezspire. However, concerns about competitive positioning and the FDA's proposed withdrawal of Tavneos may hinder the company's long-term revenue potential. Additionally, while sales of Uplizna exceeded expectations, significant increases in revenue estimates may not be sustainable. These fundamental factors lead to a neutral outlook for AMGN's stock.

Amgen (AMGN) has been analyzed by 22 analysts, with a consensus rating of Hold. 14% of analysts recommend a Strong Buy, 27% recommend Buy, 55% suggest Holding, 5% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Amgen and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Amgen (AMGN) Forecast

Analysts have given Amgen (AMGN) a Hold based on their latest research and market trends.

According to 22 analysts, Amgen (AMGN) has a Hold consensus rating as of Aug 13, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $383.32, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $383.32, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Amgen (AMGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.